MedPath

Angioplasty of Distal Lesions for Carriers of Inoperable Post-embolic HTP

Not Applicable
Completed
Conditions
Pulmonary Hypertension
Registration Number
NCT02844036
Lead Sponsor
University Hospital, Grenoble
Brief Summary

Currently, the standard treatment for proximal thromboses lesions responsible for post-embolic pulmonary hypertension, is the surgical thromboendarterectomy. When the ravages are judged too distal or the patient is judged inoperable for a curative surgical gesture, there is no evidence of any therapeutic option, exept for K anti-vitamins for recurrent embolism. Prognosis is then pejorative with a 60% mortality at 5 years.

This study propose an alternative treatment for these patients in therapeutic "dead end". This is about applying arterial thrombosis technique to the pulmonary circulation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria
  • Patients over 18 years
  • Patients with a pulmonary hypertension diagnosed by right catheterisation, with a mean arterial pressure >30 mmHg and arterial pulmonary resistance > 3 UW.
  • Patients with group 4 (Dana point) pulmonary hypertension, thromboembolic.
  • Chronic thrombosis visible to scanner, pulmonary IRM angiogram or to pulmonary angiogram.
  • Patient's file refused by the reference center multidisciplinary coordination meetings for surgical thromboendartériectomy or refusal from the patient to be operate.
  • Absence of counter-argument to the femoral venous or jugular way.
  • Normal kidney function or moderatly degraded (clearance>30 mL) or dialysed renal failure
  • Persons affiliated to national social security
  • Signed free consent by patients
Exclusion Criteria
  • Pulmonary hypertension pos-embolic operated by thromboendarteriectomy
  • Pulmonary hypertension Group 1 of Dana Point, meaning idiopathic, familial, post-anorectics, associate with a congenital heart disease associated to a scleroderma, associated to a chronic hemolytic disease
  • Pulmonary hypertension Group 2 of Dana Point, associated with a left cardiovascular disease
  • Pulmonary hypertension Group 3 of Dana Point, associated to a respiratory disease
  • Pulmonary hypertension Group 5 of Dana Point, of unclear or multifactorial mechanism
  • Hypersensitivity to HEXABRIX, to iodinated contrast product or one of its components
  • Obvious thyrotoxicosis
  • Protected major persons
  • Pregnant or breastfeeding women
  • Persons deprived of liberty
  • Persons in emergency situations.
  • No consent signed or approoved
  • Persons no affiliated to national social security

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Percutaneous angioplastyAbout 90 minutes

International Normalized Ratio wil be measure and need to be between 2 and 3.

Heart rateFew minutes

Heart rate (bpm) during right heart catheterization.

Right heart catheterizationFew minutes

Right auricular pressure auriculaire droite moyenne ou POD (mmHg)

* Blood pressure : systolic, diastolic, and average(mmHg)

* pression artérielle pulmonaire d'occlusion (PAPO) moyenne (mmHg)

Functional respiratory investigationsAbout an hour

* Forced expiratory volume (FEV) ml/kg

* Forced vital capacity (FVC) ml/kg

* Total lung capacity ml/kg

* Alveolar capillarytransfer of Carbon monoxide (CO) ml/kg

* Transfer coefficient of CO (KCO) ml/kg

All volumes in ml/kg

Balloon angioplastyAbout 90 minutes

Same mode than valscular or coronal angioplasty.

Venous oxygen saturation (%)Few minutes

Venous oxygen saturation (%) during right heart catheterization.

Walking test6 minutes

Arterial blood saturation in oxygen measured by an oxymeter dat the beginning (T0) and at the end of the test (T6) (SO2)

EchocardiographyFew minutes

Right ventricular heart function with evaluation of :

Cardiac output (L/min) and cardiac index (L/min/m²)

Pulmonary tomography or pulmonary angiographyAbout 30 minutes

tomography (CT) or angiography

Cardiac output (L/min)Few minutes

Cardiac output (L/min) during right heart catheterization.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UniversityHospitalGrenoble

🇫🇷

La Tronche, France

UniversityHospitalGrenoble
🇫🇷La Tronche, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.